Skip to main content
. 2015 Oct 22;7(1):860–872. doi: 10.18632/oncotarget.6205

Figure 2. GDF15 promotes EMT in HT29 and SW480 cells.

Figure 2

a. Immunoblotting assay for expression of E-cadherin, MMP9, Twist and vimentin in GDF15 overexpression HT29 and SW480 cells. b. Immunofluorescence assay for expression of E-cadherin and vimentin in GDF15 overexpression SW480 cells. c. Migration assay for HT29 and SW480 cells with rhGDF15 treatment (quantification in right panels). d. Immunoblotting for E-cadherin, MMP9, Twist and vimentin in HT29 and SW480 cells with rhGDF15 treatment.